Treatment references

Part 2

Malik A. Samsung Bioepsis Scores EMA Approval for Benepali, the First Etanercept biosimilar to be approved in Europe. Available at https://decisionresourcesgroup.com/drg-blog/drug-watch/samsung-bioepsis-scores-ema-approval-for-benepali-the-first-etanercept-biosimilar-to-be-approved-in-europe/. Accessed October 2016.

Matoula T, Kostopoulos N, Kyriazis N, Panagakis P. Psoriasis. Long-term efficacy and safety of infliximab maintenance therapy after 104 weeks of treatment in 50 patients with plaque-type psoriasis. EADV. Copenhagen, Denmark. 7–11 October, 2015. P1663.

Mease P, Armstrong A. Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis. Drugs 2014;74:423–41.

Mease PJ, McInnes IB, Gottlieb AB, Widmer A, Pricops L, Mpofu S, et al. Secukinumab safety and tolerability I n patients with active psoriatic arthtitis and psoriasis: Results from pooled safety analysis. Arthritis Rheumatol. 2015;67 (suppl 10). 2886.

Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate to severe plaque psoriasis. J Am Acad Dermatol. 2007;31:e1–15.

Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized controlled phase III trial. J Am Acad Dermatol. 2008;58:106–15.

Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60:643–59.

Menter A, Thaçi D, Papp KA, Wu JJ, Bereswill M, Teixeira HD, et al.  Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. J Am Acad Dermatol. 2015;73:410–9.

Menter A, Papp KA, Gooderham M, Pariser DM, Augustin M, Kerdel FA, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016a;30:1148–58.

Menter A, Cather JC, Jarratt M, Meng X, Guana A, Nyirady J. Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies. Dermatol Ther (Heidelb). 2016b;6:639–647.

Menter MA, Papp KA, Cather J, Leonardi C, Pariser DM, Krueger JG, et al. Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials.J Drugs Dermatol. 2016c;15:568–80.

Menter A, Sobell J, Silverberg JI, Lebwohl M, Rastogi S, Pillai R, et al. Long-term Efficacy of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: Data from a Pivotal Phase 3 Clinical Trial. Winter Clinical Dermatology Conference. Lahaina Hawaii. January 12-17, 2018. Poster 147. Available at https://jofskin.org/index.php/skin/article/view/253/257 (accessed March 2019)

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019. [Epub ahead of print].

Methofill Summary of Product Characteristics. 2018. Available at https://www.medicines.org.uk/emc/product/9057/smpc.

Methotrexate 10 mg tablets Summary of Product Characteristics. 2015. Available at https://www.medicines.org.uk/emc/product/9057/smpc.

Mrowietz U, Barker J, Boehncke W-H, Iversen L, Kirby B, Naldi L, et al. Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. J Eur Acad Dermatol Venereol. 2018;32:3–14.

Mrowietz U, Leonardi CL, Girolomoni G, Toth D, Morita A, Balki SA, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73:27–36.

Mrowietz U, Szepietowski JC, Loewe R, Van de Kerkhof P, Lamarca R, Ocker WG, et al. Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: A randomised, double-blind, Fumaderm® and placebo-controlled trial (BRIDGE). Br J Dermatol. 2017;176:615–23.

Naldi L and Griffiths CEM. Traditional Therapies in the Management of Moderate to Severe Chronic Plaque Psoriasis: An Assessment of the Benefits and Risks. Br J Dermatol. 2005;152:597–615.

Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, et al; Deutsche Dermatologische Gesellschaft (DDG); Berufsverband Deutscher Dermatologen (BVDD). S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges. 2012;10(suppl 2):S1–95.

Nast A, Gisondi P, Ormerod AD, Saiag P, Smith C, Spuls PI, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short version - EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29:2277–94.

Nast A, Spuls PI, van der Kraaij G, Gisondi P, Paul C, Ormerod AD et al. European S3-Guideline on the systemic treatment of psoriasis vulgaris – update apremilast and secukinumab – EDF in cooperation with EADV and IPC. J Eur Aad Dermatol Venereol. 2017;31:1951–63.

Neoral Soft Gelatin Capsules Summary of Product Characteristics. 2016. Available at https://www.medicines.org.uk/emc/product/1034/smpc.

Nguyen C, Beroukhim K, Danesh M, Leon A, Sorenson E, Huynh M, et al. A single-center, open-label study assessing the change in psychosocial and occupational well-being before and after treatment with ustekinumab in patients with moderate-to-severe psoriasis. 23rd World Congress of Dermatology. Vancouver, Canada. June 8–13, 2015. Abstract 2983379.

Nograles KE, Davidovici B, Kreuger KG. New insights into the immunological basis of psoriasis. Semin Cutan Med Surg. 2010;29:3–9.

Novartis Pharmaceuticals. Summary of Product Characteristics, Cosentyx 150 mg solution for injection. February 2015 [cited 16 April 2015]. Available from:  https://www.medicines.org.uk/emc/medicine/29848.

Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy and effect of dose reductions. Br J Dermatol. 2005;152:1304–12.

Papp KA, Langle RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody in patients with psoriasis: 52 week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675–84.

Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015a;73:37–49.

Papp K, Gottlieb AB, Naldi L, Pariser D, Ho V, Goyal K, et al. Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol. 2015b;14:706–14.

Papp K, Reich K, Leonardi C, Paul C, Bluavelt A, Baran W, et al. AMAGINE-1: A Phase 3 randomized, double-blind, placebo-controlled study of brodalumab in subjects with psoriasis. 23rd World Congress of Dermatology. Vancouver, Canada. June 8–13, 2015c. Abstract 2981945.

Papp K, Thaçi D, Reich K, Riedl E, Langley RG, Krueger JG, et al. Tildrakizumab (MK-3222), an Anti- IL-23p19 Monoclonal Antibody, Improves Psoriasis in a Phase 2b Randomized Placebo- Controlled Trial. Br J Dermatol. 2015d;173:930–9.

Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, Langley R, et al. OPT Pivotal 1 and OPT Pivotal 2 Investigators. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two, randomised, placebo-controlled, Phase 3 trials. Br J Dermatol. 2015e;173:949–61.

Papp K, Pariser D, Catlin M, Wierz G, Ball G, Akinlade B, et al. A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2015f Sep;173:767–76.

Papp KA, Armstrong AW, Reich K, Karunaratne M, Valdecantos W. Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials. Am J Clin Dermatol. 2016a;17(1):79–86.

Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016b;175:273–86.

Papp KA, Krueger JG, Feldman SR, Langley RG, Thaçi D, Torii H, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol. 2016c;74(5):841–50.

Papp K, Menter MA, Raman M, Disch D, Schlichting DE, Gaich C, et al. A Randomized Phase 2b Trial of Baricitinib, an Oral JAK1/JAK2 Inhibitor, in Patients with Moderate-to-Severe Psoriasis. Br J Dermatol. 2016d;174:1266–76.

Papp K, Reich K, Blauvely A, Thaçi D, Sinclair R, Tyring SK, et al. Clinical efficacy of tildrakizumab with chronic plaque psoriasis over 2 years of treatment: Result from long-term extension to 2 phase 3 clinical studies. Presented at the 13th Winter Clinical Dermatology Conference. January 12‒17, 2018a. Maui, HI, USA.

Papp KA, Maari C, Rich P, Klekotka P, Li J, Tuttle J, at al. Response to mirikizumab at Week 52 among patients who did not achieve a PASI 90 response at Week 16. Presented at 27th European Academy of Dermatology and Venerology Congress, 12–16 September 2018b. P1932.

Papp K, Gordon K, Taçi D, Morita A, Gooderham M, Foley P, et al. Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. N Engl J Med. 2018c;379:1313–21.

Paris – Business Wire. Janssen’s Tremfya® improves long-term patient-reported outcomes in patients with moderate to severe plaque psoriasis. Available at: https://www.businesswire.com/news/home/20180912005550/en/Janssen%E2%80%99s-TREMFYA%C2%AE%E2%96%BC-Improves-Long-Term-Patient-Reported-Outcomes-Patients. (Accessed October 2018).

Pariser D, Wu JJ, Strober B, Bagel J, Song M, Shen Y-K, et al. Drug survival is superior among patients treated with guselkumab compared to adalimumab in the VOYAGE 1 trial. Presented at 27th European Academy of Dermatology and Venerology Congress, 12–16 September 2018. P1937.

Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A. et al. European S3 guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venerol. 2009;23(suppl 2):5–70.

Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173:1387–99.

Paul C, Lacour J-P, Tedremets L, Kreutzer K, Jazayeri S, Adams S, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29:1082–90.

Paul C, Griffiths CEM, van de Kerkhof PCM, Puig L, Dutronc Y, Henneges C, et al. Ixekizumab provides superior efficacy compared to ustekinumab over 52-weeks of treatment: results from IXORA-S, a phase 3 study. J Am Acad Dermatol. 2018;. [Epub ahead of print].

Pfizer Limited. Summary of Product Characteristics, Enbrel 50 mg solution for injection in pre-filled syringe. April 2015 [cited 31 July 2015]. Available from: https://www.medicines.org.uk/emc/product/273/smpc.

PharmaTimes. Abbott withdraws briakinumab applications in USA, Europe. January 2011 [cited 16 May 2016]. Available from:  http://www.pharmatimes.com/article/11-01-17/Abbott_withdraws_briakinumab_applications_in_USA_Europe.aspx.

Prescribing Information Olumiant, 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207924s000lbl.pdf

Prescribing Information Taltz, 2017. Available from: https://www.janssenmd.com/pdf/tremfya/tremfya_pi.pdf (Accessed October 2018).

Prescribing Information, Xeljanz, 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203214s018lbl.pdf.

Puig L, Carretero G, Daudén E, Ferrándiz C, Marrón SE, Martorell A, et al. Biosimilars in Dermatology: Current Situation (Part I). Actas Dermosifiliogr. 2015;106:545–9.

Puig L, Thom H, Mollon P, Tian H, Ramakrishna GS. Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2017;31:213–20.

Rich P, Gooderham M, Bachelez H, Goncalves J, Day RM, Chen R, Crowley J. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol. 2016;74:134–42.

Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate to severe psoriasis: A phase III multicentre, double-blind trial. Lancet. 2005;366:1367–74.

Reich K, Langley RG, Papp KA, Ortonne JP, Unnebrink K, Kaul M, Valdes JM. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med. 2011;365:1586–96.

Reich K, Ortonne JP, Gottlieb AB, Terpstra IJ, Coteur G, Tasset C, Mease P. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol. 2012;167:180–90.

Reich K, Sullivan J, Arenberger P, Morwietz U, Regnault, P, Chen P, et al. Secukinumab is effective in subjects with nail psoriasis: 16 week results from the transfigure study. 23rd World Congress of Dermatology. Vancouver, Canada. June 8–13, 2015. Abstract 3086561.

Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol. 2016a;31:507–17.

Reich K, Leonardi C, Lebwohl M, Kerdel F, Okubo Y, Romiti R, et al. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). J Dermatolog Treat. 2017b;28:282–7.

Reich K, Blauvelt A, Armstrong A, Langley RG, Fox T, Huang J, et al. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in subjects with moderate to severe plaque psoriasis. Br J Dermatol. 2017a;176:752–8.

Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017b;76:418–31.

Reich K, Griffiths CEM, Iversen L, Peserico A, Pau-Charles I, Blauvelt A, et al. Improvements in dermatology-specific health-related quality of life in patients with moderate-to-severe psoriasis treated with tildrakizumab: pooled results from reSURFACE 1 and reSURFACE 2 phase 3 trials. Presented at 27th European Academy of Dermatology and Venerology Congress, 12–16 September 2018. P1919.

Reich K, Maari C, Heredia EE, Zhu B, Kletoka P, Li J, et al. Mirikizumab improves patient-reported signs and symptoms of psoriasis. Presented at 27th European Academy of Dermatology and Venerology Congress, 12–16 September 2018b. P1823.

Reich K, Nielsen VS, Hansen J, Ghys L, Warren R. Achieving complete clearance in the AMAGINE-2 and -3 studies: complete clearance over time in patients with moderate to severe plaque psoriasis treated with brodalumab up to 52 weeks. Presented at 27th European Academy of Dermatology and Venerology Congress, 12–16 September 2018a. FC03.06.

Reich K, Papp K, Blauvelt A, Tyring SK, Sinclair R, Thaci D, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised, controlled, phase 3 trials. Lancet. 2017c;390(10091):276-288.

Reich K, Gooderham M, Thaçi D, Crowley JJ, Ryan C, Krueger JG et al. Efficacy and safety of continuous risankizumab or switching from adalimumab to risankizumab treatment in patients with moderate-to-severe plaque psoriasis: Results from the phase 3 IMMvent trial. 2019 AAD Annual Meeting, Washington DC, 01–05 March 2019. 10218. Available at: https://www.aad.org/eposters/Submissions/getFile.aspx?id=10218&type=sub (accessed March 2019). 

Remicade Summary of Product Characteristics. 2018. Available at https://www.medicines.org.uk/emc/product/3831.

Remsima Summary of Product Characteristics. 2018. Available at https://www.medicines.org.uk/emc/product/3709.

Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol. 2012;66:369–75.

Rouse NC, Farhangian ME, Wehausen B, Feldman SR. The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis. Expert Rev Pharmacoecon Outcomes Res. 2015;15:877–84.

Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: A meta-analysis of randomized controlled trials. JAMA. 2011;306:864–71.

Sanford M, McKage K. Secukinumab: First global approval. Drugs. 2015;75:329–38.

Saunte DM, Mrowietz U, Puig L, Zachariae C. Candida infections in psoriasis and psoriatic arthritis patients treated with IL-17 inhibitors and their practical management. Br J Dermatol. 2017;177(1):47-62.

Saurat JH, Dubertret SG, Papp K. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158:558–66.

Schreiber S, Sands BE, Deodhar A, Baeten D, Huang J, Gandhi K, et al. No increased incidence of inflammatory bowel disease among secukinumab-treated patients with moderate to severe psoriasis, psoriatic arthritis, or ankylosing spondylitis: data from 14 phase 2 and phase 3 clinical studies. Ann Rheum Dis 2016;75(Suppl2):97.

Segaert S, Andersen J, Nielsen VS, Ghys L, Zachariae C. Efficacy of brodalumab, an interleukin-17 receptor antibody, on clinical signs of moderate-to-severe plaque psoriasis in different body regions. Presented at 27th European Academy of Dermatology and Venerology Congress, 12–16 September 2018. P0457.

Shear NH, Hartmann M, Toledo-Bahena ME3 Gilbert M, Katsambas A, Yao R, Popmihajlov Z. Health-related quality-of-life improvements during 98 weeks of infliximab therapy in patients with plaque-type psoriasis in real-world practice. Qual Life Res. 2016;25:2031–40.

Skilarence® Summary of Product Characteristics. 2018. Available at https://www.medicines.org.uk/emc/product/752/smpc (accessed November 2018).

Sofen H, Smith S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol. 2014;133:1032–40.

Solymbic Summary of Product Characteristics. 2018. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004373/WC500225364.pdf.

Stein Gold L, Bagel J, Lebwohl M, Jackson JM, Chen R, Goncalves J, et al. Efficacy and safety of apremilast in systemic- and biologic-naive patients with moderate plaque psoriasis: 52-week results of UNVEIL. J Drugs Dermatol. 2018;17(2):221–8.

Stein GL, Bagel J, Lebwohl MG, Lin T, Martin G, Pillai R. Halobetasol and tazarotene: further defining the role of a unique fixed combination topical lotion in moderate-to-severe plaque psoriasis. J Drugs Dermatol. 2018;17:1290–6.

Strober B, Mordin M, Mollons P, Williams N, Fox T, Papavassilis, et al. Secukinumab demonstrates greater impact on patient global impression of change than etancercept in moderate to severe psoriasis. EADV. Copenhagen, Denmark. 7–11 October 2015. P1702.

Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, et al. Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. Int J Dermatol. 2016a;55:401–7.

Strober BE, Bissonnette R, Fiorentino D, Kimball AB, Naldi L, Shear NH, et al. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). J Am Acad Dermatol. 2016s;74:851–861.e4.

Strober B, Papp KA, Lebwohl M, Reich K, Paul C, Blauvelt A, et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol. 2016b;75(1):77–82.

Strober B, Leonardi C, Papp KA, Mrowietz U, Ohtsuki M, Bissonnette R, et al. Short and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. J Am Acad Dermatol. 2017a;76:432–40.e17.

Strober B, Gottlieb AB, Sherif B, Mollon P, Gilloteau I, McLeod L, et al. Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. J Am Acad Dermatol. 2017b;76:655–61.

Strober B, Bagel J, Lebwohl M, Stein Gold L, Jackson JM, Chen R, et al. Efficacy and safety of apremilast in patients with moderate plaque psoriasis with lower BSA: Week 16 results from the UNVEIL study. J Drugs Dermatol. 2017;16(8):801–8.

Strober B, Lambert J, Gu Y, Thompson EHZ, Valdecantos W, Menter A. Impact of prior treatment history on efficacy of risankizumab compared with placebo in patients with moderate-to-severe plaque psoriasis: integrated analyses from three phase 3 trials. Presented at 27th European Academy of Dermatology and Venerology Congress, 12–16 September 2018. P1867.

Summary of Product Characteristics, Benepali, 2018. Available from: https://www.medicines.org.uk/emc/product/1987/smpc.

Summary of Product Characteristics, Cosentyx, 2015 [cited 28 April 2016]. Available from: https://www.medicines.org.uk/emc/medicine/29848.

Summary of Product Characteristics, Cimzia, 2018 [cited 13 July 2018]. Available from: https://www.medicines.org.uk/emc/product/4450/smpc.

Summary of Product Characteristics, Enbrel, 2015 [cited 5 December 2015]. Available from: https://www.medicines.org.uk/emc/print-document?documentId=3343.

Summary of Product Characteristics, Erelzi, 2018. Available from: https://www.medicines.org.uk/emc/product/634.

Summary of Product Characteristics, Flixabi, 2018. Available from: https://www.medicines.org.uk/emc/product/7265.

Summary of Product Characteristics, Humira, 2016 [cited 28 April 2016]. Available from: https://www.medicines.org.uk/emc/medicine/21201.

Summary of Product Characteristics, Inflectra, 2018. Available from: https://www.medicines.org.uk/emc/product/3710.

Summary of Product Characteristics, Kyntheum, 2017. Available from: https://www.medicines.org.uk/emc/product/751.

Summary of Product Characteristics, Otezla, 2015 [cited 5 December 2015]. Available from: https://www.medicines.org.uk/emc/print-document?documentId=29792.

Summary of Product Characteristics, Olumiant, 2018. Available from: https://www.medicines.org.uk/emc/product/2434/smpc.

Summary of Product Characteristics, Remicade, 2015 [cited 28 April 2016]. Available from: http://www.medicines.org.uk/emc/medicine/3236.

Summary of Product Characteristics, Remsima, 2018. Available from: https://www.medicines.org.uk/emc/product/3709.

Summary of Product Characteristics, Stelara, 2015 [cited 28 April 2016]. Available from: https://www.medicines.org.uk/emc/product/4412/smpc.

Summary of Product Characteristics, Tremfya, 2017. Available from: https://www.medicines.org.uk/emc/product/8662.

Sun Pharma press release. Sun Pharma announces receipt of European Commission approval for ILUMETRI® (tildrakizumab) by Almirall for treatment of moderate-to-severe chronic plaque psoriasis.Available from: www.sunpharma.com/Media/Press-Releases/Press%20Release%20European%20Commission%20Approval%20For%20ILUMETRI.pdf (Accessed September 2018).

Tan H, Valdez H, Griffiths C, Mrowietz U, Tallman A, Wolk R, Gordon K. Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis. J Dermatolog Treat. 2017;28:3–7.

Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomised controlled trial. J Am Acad Dermatol 2015;73:400–9.

Thaçi D, Kimball A, Foley P, Poulin Y, Levi E, Chen R, Feldman SR. et al. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: Results of two phase III randomized, controlled trials. J Eur Acad Dermatol Venereol. 2017;31:498–506.

Thaci D, Griffiths CEM, Iversen L, Peserico A, Kimball AB, Pau-Charles I et al.Long-term efficacy of tildrakizumab in patients with moderate-to-severe psoriasis who were non-responders or partial responders to etanercept in the phase 3 reSURFACE2 trial. Presented at 27th European Academy of Dermatology and Venerology Congress, 12–16 September 2018a. P1923.

Thaçi D, Von Kiedrowski R, Koerber A, Bachhuber T, Kasparek T, Duetting E, et al. Secukinumab real-world effectiveness data on plaque psoriasis treatment in Germany corroborate pivotal clinical trial results: Analysis of the first 2,000 subjects enrolled in the PROSPECT study. Presented at 27th European Academy of Dermatology and Venerology Congress, 12–16 September 2018b. P1994.

Thaci D, Termeer C, Sebastian M, Pinter A, Sticherling M, Gerdes S, et al. Guselkumab is superior to fumaric acid esters in patients with moderate to severe plaque psoriasis who are naive to systemic treatment: Initial results from the Phase 3b POLARIS trial. Presented at 27th European Academy of Dermatology and Venerology Congress, 12–16 September 2018c. OP01.05.

Thomas B, Collier P, Favata MF, Wen X, Shi J, McGee R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 2010; 184:5298–307.

Tremfya® Prescribing Information, 2017. Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761061s000lbl.pdf. (Accessed February 2019).

Tremfya® efficacy data in patients with moderate to severe plaque psoriasis. Available from: https://www.tremfyahcp.com/efficacy/open-label-extension-data (Accessed October 2018).

Tyring S, et al. Efficacy and Safety of Long-term Tildrakizumab for Plaque Psoriasis: 3-Year Results From reSURFACE 1. 2019 AAD Annual Meeting, Washington DC, 01–05 March 2019. Available at: https://www.aad.org/eposters/Submissions/getFile.aspx?id=10508&type=sub (accessed March 2019).

U.S. Food and Drug Administration. FDA News Release, FDA approves new psoriasis drug Cosentyx. January 2015 [cited 5 December 2015]. Available from: http://wayback.archive-it.org/7993/20180126023512/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm430969.htm.

U.S. Food and Drug Administration. Ilumya prescribing information. 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761067s000lbl.pdf

Vaclavkova A, Chimenti S, Arenberger P, Holló P, Sator PG, Burcklen M, et al. Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014;384:2036–45.

Valeant press release. FDA Advisory Committee Recommends Approval Of Brodalumab For Treatment Of Moderate-To-Severe Plaque Psoriasis [cited 30 January 2017]. Available from: http://ir.valeant.com/news-releases/2016/07-19-2016-212752481.

Valenzuela F, Paul C, Mallbris L, Tan H, Papacharalambous J, Valdez H, Mamolo C. Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study. J Eur Acad Dermatol Venereol. 2016;30:1753–9.

van de Kerkhof PC, Reich K, Kavanaugh A, Bachelez H, Barker J, Girolomoni G, et al.  Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. J Eur Acad Dermatol Venereol. 2015;29:2002–10.

van de Kerkhof PC, Griffiths CE, Reich K, Leonardi CL, Blauvelt A, Tsai TF, et al. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75:83–98.

van de Kerkhof P, Guenther L, Gottlieb AB, Sebastian M, Wu JJ, Foley P, et al. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3. J Eur Acad Dermatol Venereol. 2017;31:477–82.

Vilarrasa E, Notario J, Bordas X, López-Ferrer A, Gich IJ, Puig L. ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice. J Am Acad Dermatol. 2016;74:1066–72.

Warren RB, Finlay AY, Barker J, Burden A, Armendariz Y, Williams R, et al. The efficacy and safety of secukinumab in psoriasis patients classed as non-responders to anti-TNF alpha therapy; 72 week data from the SIGNATURE study. Presented at 27th European Academy of Dermatology and Venerology Congress, 12–16 September 2018. P1981.

Wong T, Hsu L, Liao W. Phototherapy in psoriasis: a review of mechanisms of action. J Cutan Med Surg. 2013;17:6–12.

Wu JJ, Strober BE, Hansen PR, Ahlehoff O, Egeberg A, Qureshi AA, et al. Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis. J Am Acad Dermatol. 2016;75:897–905.

Yamauchi PS, Bagel J. Next-generation biologics in the management of plaque psoriasis: A literature review of IL-17 inhibition. J Drugs Dermatol. 2015;14:244–50.

Yan K, Zhang Y, Han L, Huang Q, Zhang Z, Fang X, et al. Safety and efficacy of methotrexate for Chinese adults with psoriasis and without psoriatic arthritis. JAMA. 2019. Epub ahead of print.

Yamazaki S, Inamia M, Ito M, Fujii Y, Hanaoka K, et al. ASP015K: a novel JAK inhibitor demonstrated potent efficacy in adjuvant-induced arthritis model in rats. Arthritis Rheum 2012; 64(Suppl. 10):2084.

Yiu ZZ, Warren RB. Efficacy and safety of emerging immunotherapies in psoriasis. Immunotherapy. 2015;7:119–33.

Zaba LC, Krueger JG, Lowes MA. Resident and "inflammatory" dendritic cells in human skin. J Invest Dermatol. 2009;129(2):302–8.

Zweegers J, Groenewoud JM, van den Reek JM, Otero ME, van de Kerkhof PC, Driessen RJ, et al. Comparison of the one and 5-years effectiveness of adalimumab, etanercept and ustekinumab in psoriasis patients in daily clinical practice: Results from the prospective BioCAPTURE registry. Br J Dermatol. 2017;176:1001–9.